Business
Parexel and NeoGenomics Announce Strategic Collaboration in Precision Medicine to Improve Study Designs and Accelerate Patient Matching in Oncology Clinical Trials
Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and
About this update from Neogenomics, Inc.
[{"type":"text","content":"Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and translational research\nBOSTON and DURHAM, N.C. and FT. MYERS, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, and NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced a strategic partnership to advance the application of precision medicine in oncology clinical trials by applying real-world genomics data to accelerate patient matching and optimize trial design, site selection, clinical development and translational research. The collaboration with NeoGenomics will enhance Parexel’s use of real-world data across various applications, including identifying and estimating prevalence of genomic mutations within respective populations, genomic patterning to stratify patients according to novel biomarkers, and use of de-identified patient data to precisely target patient populations. Collectively these data are designed to better inform clinical trial feasibility, enhance patient matching and create a holistic view of the patient journey by linking genomic data with clinical and consumer datasets. The collaboration will ultimately enable researchers to quickly enroll patients with common to rare cancer mutations and connect them to clinical trials providing the best likelihood of potential treatment success. “Parexel’s partnership with NeoGenomics provides access to greater predictive modeling capabilities so that we can rapidly identify specific patients and connect them to clinical trials that provide them with the best potential for treatment, advance our understanding of their disease and identify the drug’s effects and potential benefits,” said Sy Pretorius, MD, President, Clinical Development and Chief Medical Officer at Parexel. “This collaboration supports our efforts to adopt more novel approaches in the identification of data populations for oncology studies while keeping the patient at the center of everything we do.” “We are thrilled to collaborate with Parexel to provide our robust genomic and clinical database ...